MedTrace Logo

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-04-01

No results posted yet for this study

Summary

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Conditions

Interventions

DRUG

ECC4703

orally QD

DRUG

Placebo

orally QD

DRUG

Semaglutide

SC once weekly

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-13
Primary Completion
2026-11-20
Completion
2026-11-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07505303 on ClinicalTrials.gov